Gilead Sciences Inc. (GILD)

66.94
NASDAQ : Health Technology
Prev Close 68.07
Day Low/High 66.50 / 68.20
52 Wk Low/High 60.32 / 79.61
Avg Volume 6.38M
Exchange NASDAQ
Shares Outstanding 1.27B
Market Cap 86.55B
EPS 4.20
P/E Ratio 9.67
Div & Yield 2.52 (3.62%)

Latest News

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion

Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion

Gilead Sciences said Monday that it will boost its stake in Belgian listed biotech Galapagos NV by more than $5 billion in a "transformative" deal that could tap new opportunities for the California-based group in fibrosis and arthritis.

I'm Looking at Gilead and Merck for Buy Entry Positions

I'm Looking at Gilead and Merck for Buy Entry Positions

Let's see if either of these names provide an entry this week.

Gilead And Galapagos Enter Into Transformative Research And Development Collaboration

Gilead And Galapagos Enter Into Transformative Research And Development Collaboration

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that they have entered into a 10-year global research and development collaboration.

Active vs. Passive Investing: What's the Difference?

Active vs. Passive Investing: What's the Difference?

Some investors like to buy and hold, others choose to be hands-on—buying, selling and capitalizing on short-term profits.

Gilead Appoints Christi L. Shaw As Chief Executive Officer Of Kite

Gilead Appoints Christi L. Shaw As Chief Executive Officer Of Kite

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Christi L.

Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences And Renown Institute For Health Innovation Announce Strategic Collaboration To Advance Understanding Of Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic...

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

Gilead Announces Intent To Submit New Drug Application For Filgotinib To U.S. Food And Drug Administration This Year

Gilead Announces Intent To Submit New Drug Application For Filgotinib To U.S. Food And Drug Administration This Year

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that at a recent pre-New Drug Application (NDA) meeting with the U.

3 Autopilot Funds for a High-Yield Portfolio

3 Autopilot Funds for a High-Yield Portfolio

This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.

Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming To Eliminate The Disease

Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming To Eliminate The Disease

Today, Governor John Bel Edwards joined Secretary Rebekah Gee of the Louisiana Department of Health, Secretary James LeBlanc of the Louisiana Department of Corrections, and Asegua Therapeutics LLC, a wholly-owned subsidiary of Gilead Sciences, Inc.

Gilead And Carna Biosciences Announce Research And Development Collaboration To Develop Novel Immuno-Oncology Therapies

Gilead And Carna Biosciences Announce Research And Development Collaboration To Develop Novel Immuno-Oncology Therapies

Gilead Sciences, Inc. (NASDAQ: GILD) and Carna Biosciences Inc.

Gilead And Nurix Establish Strategic Collaboration To Develop Novel Therapies For Cancer And Other Diseases

Gilead And Nurix Establish Strategic Collaboration To Develop Novel Therapies For Cancer And Other Diseases

Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc.

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Kite Announces New Yescarta® Data From ZUMA-1

Kite Announces New Yescarta® Data From ZUMA-1

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses from the ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.

Kite Announces End Of Phase 1 ZUMA-3 Results For KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite Announces End Of Phase 1 ZUMA-3 Results For KTE-X19 In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy.

Kite And Humanigen Announce Clinical Collaboration To Evaluate Investigational Combination Of Yescarta® (Axicabtagene Ciloleucel) With Lenzilumab In Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kite And Humanigen Announce Clinical Collaboration To Evaluate Investigational Combination Of Yescarta® (Axicabtagene Ciloleucel) With Lenzilumab In Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta ® (axicabtagene...

Gilead And Galapagos To Present Latest Data On Filgotinib At The Annual European Congress Of Rheumatology (EULAR 2019)

Gilead And Galapagos To Present Latest Data On Filgotinib At The Annual European Congress Of Rheumatology (EULAR 2019)

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in...

Gilead Sciences Appoints Johanna Mercier As Chief Commercial Officer

Gilead Sciences Appoints Johanna Mercier As Chief Commercial Officer

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Johanna Mercier will join the company as Chief Commercial Officer, and will become a member of the company's senior leadership team.

Gilead Sciences Slips on Goldman's Downgrade to Sell

Gilead Sciences Slips on Goldman's Downgrade to Sell

Shares of Gilead Sciences fall after Goldman Sachs downgrades the stock to sell from neutral.

Gilead Sciences To Present At The Jefferies 2019 Global Healthcare Conference On Wednesday, June 5

Gilead Sciences To Present At The Jefferies 2019 Global Healthcare Conference On Wednesday, June 5

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2019 Global Healthcare Conference in New York on Wednesday, June 5 at 11:30 a.

Kite To Present New Data From Leading Cell Therapy Portfolio At ASCO 2019

Kite To Present New Data From Leading Cell Therapy Portfolio At ASCO 2019

Kite, a Gilead Company (Nasdaq: GILD), today announced that new data from its cell therapy programs will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from May 31 - June 4, 2019.

Gilead Sciences To Provide Free Truvada For PrEP® To Support U.S. Initiative To End The HIV Epidemic

Gilead Sciences To Provide Free Truvada For PrEP® To Support U.S. Initiative To End The HIV Epidemic

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP ® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.

Gilead Sciences And Goldfinch Bio Announce Strategic Collaboration To Develop Novel Therapies For Kidney Disease

Gilead Sciences And Goldfinch Bio Announce Strategic Collaboration To Develop Novel Therapies For Kidney Disease

Gilead Sciences, Inc. (Nasdaq: GILD) and Goldfinch Bio, Inc.

Gilead Sciences To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On Tuesday, May 14

Gilead Sciences To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On Tuesday, May 14

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.

Gilead Sciences Has Right Prescription on First-Quarter Earnings

Gilead Sciences Has Right Prescription on First-Quarter Earnings

Gilead Sciences' adjusted earnings in the first quarter beat analysts' expectations.

Gilead Sciences Is Regaining Its Shine

Gilead Sciences Is Regaining Its Shine

Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.

Gilead Sciences Announces Second Quarter 2019 Dividend

Gilead Sciences Announces Second Quarter 2019 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

TheStreet Quant Rating: C (Hold)